Immunotherapy and targeted therapy before surgery for advanced mouth cancer
Part of Cancer, Mouth & dental clinical trials.
This trial tests two drugs, pembrolizumab and cetuximab, given before surgery to shrink advanced mouth cancer linked to betel-nut chewing. It aims to improve treatment outcomes and shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a history of chewing betel nut.
- You have oral cavity squamous cell carcinoma that is locally advanced (stage III or IV).
- You have not received any prior treatment for this cancer.
- Your cancer is measurable (can be assessed on scans).
- You are generally able to carry out daily activities (ECOG 0-3).
- You do not have distant metastasis (cancer that has spread to distant sites).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of an immunotherapy drug (Benmelstobart), a targeted therapy (Anlotinib), and standard chemotherapy given before surgery for advanced oral cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests whether adding two immunotherapy drugs (sintilimab and cetuximab) before and after surgery can improve outcomes for people with advanced mouth or throat cancer. It is for those who have not yet had treatment and whose tumors have a certain protein level (PD-L1 CPS >1).
This study tests if giving immunotherapy before surgery helps treat oral cavity cancer. Researchers will look for markers in your biopsy that predict how well the treatment works.
This trial tests whether combining two targeted drugs (cemiplimab and cetuximab) before surgery can help people with recurrent mouth or throat cancer that has come back after initial treatment. It aims to see if this approach makes surgery more effective.
This Phase 2 study tests medicines given before surgery for stage III/IV oral squamous cell carcinoma, choosing the treatment based on your tumor marker results. It aims to shrink the cancer and improve outcomes by using two targeted types of therapy.
This trial tests whether adding targeted radiation (SBRT) to a combination of chemotherapy and immunotherapy before surgery can improve outcomes for people with advanced mouth or throat cancer. It aims to shrink the tumor more effectively before removal.
Hear when a new Betel-nut-associated Oral Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.